All News

ACR Clean (Keep)

ACR Supports Legislation to Improve Oversight and Transparency of Prior Authorization Use

d Anonymous

Rheumatology Leaders Join a Coalition of National Medical Specialties in Urging Congress to Protect Patients from Prior Authorization Requirements in Medicare Advantage Plans

Read Article
RN.podcast.resized.jpg

RheumNow Podcast – Drug Ad Transparency (6.7.19)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles of note from this past week on RheumNow.com.

Read Article
ACTHAR.jpg

More Trouble for Mallinckrodt’s Acthar Gel

d Jack Cush, MD

Reuters has reported that Mallinckrodt Plc has tentatively agreed to pay $15.4 million to resolve a US Justice Department investigation into company promotional practices for Acthar gel.

Read Article
arthritis.RA_.Xray_.hands_.jpg (keep)

Low Remission/LDA Rates with TNF inhibitors in Rheumatoid Arthritis

d Jack Cush, MD

 

Read Article
CBD2.hemp_.jpg

FDA Public Review of CBD Oil

d Jack Cush, MD

The US Food and Drug Administration convened a public hearing and specialty panel on May 31st to review the potential use, safety and effectiveness of cannabidiol (CBD) products that do not contain THC.

Read Article
overweight.obesity.diet_.jpg

Proinflammatory Diets May Increase CRP and RA Onset

d Jack Cush, MD

Despite the lack of good evidence, there has been great speculation about the role of diet in causing or alleviating inflammation. Now there's new research suggesting that proinflammatory diets can increase serum C-reactive protein levels and also the risk of rheumatoid arthritis onset.

Read Article
IL17_0.jpg

Might IL-17 Inhibition Be Effective in RA?

d Jack Cush, MD

Interleukin 17 (IL-17) inhibitors are highly effective and FDA approved for use in psoriasis, psoriatic arthritis and ankylosing spondylitis. However, many of the initial trials were done in rheumatoid arthritis (RA) where it was projected to be effective, but was not. A recent metanalysis examines how effective IL-17 inhibition was in two RA populations: biologic-naïve or tumor necrosis factor inhibitor inadequate responders (TNF-IR).

Read Article
kneepain3.jpg (keep)

Knee Injuries Increases Osteoarthritis Risk

d Jack Cush, MD

A systematic review of the medical literature shows anterior cruciate ligament (ACL), meniscus or combined ACL and meniscus injury significantly increases the risk of future knee osteoarthritis (OA).

Read Article
exercise.workout.jpg

Recommendations for Exercise in Ankylosing Spondylitis

d Jack Cush, MD

Australian researchers have assessed the problem of exercise in ankylosing spondylitis (AS). After posing 10 questions to 11 experts they have provided evidence and consensus-based ecommendations on exercise in AS.

Read Article
QD Clinic - daily lessons and cases from the Rheumatology clinic. RA patient, not quite controlled, needs to optimized MTX therapy Features Dr. Jack Cush https://t.co/ZoX2biwv7M

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA sent an "untitled"letter to "R3 Stem Cell" for touting birth tissue products as Rx for ailments (without scientific evidence). FDA also won a case against "US Stem Cell clinics" for adulterated & misbranded stem cell products https://t.co/bQpRHxR9G8 https://t.co/oLBPKZ1lxX

Links:

Dr. John Cush RheumNow ( View Tweet)

Word of the day: Ischuria= urinary retention. My patient with systemic sclerosis and severe spinal stenosis developed ischuria and now has to self-cath. #rheumnow

k dao KDAO2011 ( View Tweet)

Transparency is coming? The Prices will soon be Included in TV Drug Ads. HHS Secretary Alex Azar has finalized regulations requiring drug companies to disclose list prices of medications costing more than $35 for a month’s supply. https://t.co/P2DPwXGYXK

Links:

Dr. John Cush RheumNow ( View Tweet)

The overall prevalence of gout among US adults is 3.9%, affecting 9.2 million people. Hyperuricaemia prevalence is 14.6% - affecting 32.5 million in the US. Data from NHANES NHANES 2015–16 https://t.co/3g05GmUDUA

Links:

Dr. John Cush RheumNow ( View Tweet)

Korean Natl Claims Database examined RA & risk of opportunistic infx- OI, H zoster & candidiasis are seen in early RA. SIR for OI in early RA=1.14 (95% CI, 1.05‐1.23). H zoster (1.12), candidiasis (2.40); Age, steroids & comorbidity increased OI risk https://t.co/U7LPMpmPqG

Links:

Dr. John Cush RheumNow ( View Tweet)

CDC has updated its recommendations for TB testing of health care personnel. All HCP should be tested initially but after TB risk assessment, there is no need for routine or serial TB testing in the absence of exposure or ongoing risk of TB. https://t.co/qtAdz8d7OK

Links:

Dr. John Cush RheumNow ( View Tweet)

Metformin, was given to a mouse model Sjogrens (NOD)/ShiLtJ mice) & reduced salivary inflammation, IL-6,TNFα, IL-17 mRNA, improved salivary flow rate, suppressed effector T cells, inducec regulatory T cells & B cell diff. Why are mice so easy, SS so tough? https://t.co/yC5fJIBBEx

Links:

Dr. John Cush RheumNow ( View Tweet)

Here's the application for A&R Editor position 2020-2025 https://t.co/IoyxAECAJ0

Links:

Dr. John Cush RheumNow ( View Tweet)

he American College of Rheumatology invites applications for the position of Editor, Arthritis & Rheumatology for the 2020 - 2025 term. The deadline to submit an application is June 21, 2019.

Dr. John Cush RheumNow ( View Tweet)

UK Clinical Practice Database matched 62,234 pts with and without gout showing more venous thromboembolic events in gout (0.373 vs 0.27 per 100 Pt-yrs) (aHR 1.25, 95% CI 1.15–1.35) - not affected by ULT & not significant while in hospital (aHR 1.01) https://t.co/XrInEwckez

Links:

Dr. John Cush RheumNow ( View Tweet)

×